Pressing financial resource for new medicine development

Published: 2001-06-27 06:59:00

Updated: 2001-06-27 06:59:00

KPMA insisted that reimbursement system of actual market price should be come to stay and low-profit structure should be improved for the purpose of preventing unreasonable price from reducing and settling orderly medicine trading to improve research development power of pharmaceutical manufactur...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK